(Length of Discussion: 8 min)

Tian Zhang discusses with Alicia Morgans the STARTAR trial, a phase 2 enrolling high risk prostate cancer patients with Gleason 7 T3 or Gleason 8-10 who have developed PSA recurrence and adding systemic agents to standard of care with the goal of extending the lives of this patient population. They discuss logistics for patients who may qualify for this trial.

Biographies:

Tian Zhang, MD, Assistant Professor of Medicine in the Division of Medical Oncology and the Department of Medicine and a member of the Duke Cancer Institute

Alicia Morgans, MD, MPH

Related Content: 

A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)

12-Year Follow-Up of GETUG-12, A Phase 3 Trial of Docetaxel-Based Chemotherapy in High-Risk Localized Prostate Cancer

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

ClinicalTrials.gov NCT03311555 The STARTAR Trial